GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Longevity Health Holdings Inc (NAS:XAGE) » Definitions » 5-Year EBITDA Growth Rate

XAGE (Longevity Health Holdings) 5-Year EBITDA Growth Rate : 0.00% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Longevity Health Holdings 5-Year EBITDA Growth Rate?

Longevity Health Holdings's EBITDA per Share for the three months ended in Dec. 2024 was $-0.05.

During the past 3 years, the average EBITDA Per Share Growth Rate was 38.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Longevity Health Holdings was 38.60% per year. The lowest was 38.60% per year. And the median was 38.60% per year.


Competitive Comparison of Longevity Health Holdings's 5-Year EBITDA Growth Rate

For the Household & Personal Products subindustry, Longevity Health Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longevity Health Holdings's 5-Year EBITDA Growth Rate Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Longevity Health Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Longevity Health Holdings's 5-Year EBITDA Growth Rate falls into.


;
;

Longevity Health Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Longevity Health Holdings  (NAS:XAGE) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Longevity Health Holdings 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Longevity Health Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Longevity Health Holdings Business Description

Traded in Other Exchanges
N/A
Address
2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Longevity Health Holdings Inc is a United States based bio-aesthetics company focused on developing, manufacturing, and marketing cosmetic skincare and haircare products. The company has two cosmetic product lines, Carmell Secretome and Elevai Exosomes, that support skin and hair health.
Executives
Richard A Upton director 12 MIDDLE STREET, AMHERST NH 03031
Kathryn Gregory director 305 THAYER POND ROAD, WILTON CT 06897
Patrick A Sturgeon officer: CFO and Secretary 600 LEXINGTON AVENUE 33 FLOOR, NEW YORK NY 10022
David W Anderson director 519 LYNMERE ROAD, BRYN MAWR PA 19010
Rajiv Shukla director, 10 percent owner, officer: Chief Executive Officer EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
Randolph W Hubbell director, officer: President and CEO C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William R Newlin director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Steven Bariahtaris director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Jaime Garza director C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Janet Vargo officer: VP Clinical Services C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
Donna Godward officer: Chief Quality Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
James C Hart officer: Chief Medical Officer C/O CARMELL THERAPEUTICS CORPORATION, 2403 SIDNEY STREET, SUITE 300, PITTSBURGH PA 15203
William Woodward director ANTHEM VENTURE PARTNERS, 225 ARIZONA AVENUE, SUITE 200, SANTA MONICA CA 90401
Darlene T Deremer director 200 CENTRAL AVENUE, SUITE 1850, ST. PETERSBURG FL 33701
Ahac Sponsor Iii Llc 10 percent owner 1177 AVENUE OF THE AMERICAS, 5TH FLOOR, NEW YORK NY 10036